OncoMatch/Clinical Trials/NCT06429098
Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML
Is NCT06429098 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Venetoclax and azacitidine for acute myeloid leukemia.
Treatment: Venetoclax · azacitidine · decitabine · Cytarabine — This investigator-initiated, single-arm, phase II trial is aimed to evaluate the efficacy and safety of a venetoclax-based, anthracycline-free regimen in patients with newly diagnosed CBFβ::MYH11-positive acute myeloid leukemia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: CBFB cbfβ::myh11 fusion
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Cannot have received: hypomethylating agent
Exception: oral hydroxyurea and/or leukocytometry to reduce white blood cell count
Subject has received treatment with a hypomethylating agent and/or other chemotherapeutic agents either conventional or experimental or targeted drug therapy for AML (except oral hydroxyurea and/or leukocytometry to reduce white blood cell count)
Cannot have received: chemotherapeutic agent
Exception: oral hydroxyurea and/or leukocytometry to reduce white blood cell count
Subject has received treatment with a hypomethylating agent and/or other chemotherapeutic agents either conventional or experimental or targeted drug therapy for AML (except oral hydroxyurea and/or leukocytometry to reduce white blood cell count)
Cannot have received: targeted drug therapy
Exception: oral hydroxyurea and/or leukocytometry to reduce white blood cell count
Subject has received treatment with a hypomethylating agent and/or other chemotherapeutic agents either conventional or experimental or targeted drug therapy for AML (except oral hydroxyurea and/or leukocytometry to reduce white blood cell count)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06429098 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CBFB?
Yes, CBFB cbfβ::myh11 fusion is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages